The trial comparing the gp100 vaccine alone vs. the combination with Ipilimumab in patients with metastatic melanoma showed that the vaccine did not improve the overall survival as compared to Ipilimumab alone [40]. This evidence concerns the gene PMEL and metastatic melanoma.